Advertisement
Advertisement
U.S. Markets close in 2 hrs 44 mins
Advertisement
Advertisement
Advertisement
Advertisement

Alphamab Oncology (9966.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
13.2400.000 (0.00%)
At close: 04:08PM HKT
Advertisement

Alphamab Oncology

Building C23
Rooms 401 and 501 No. 218 Xinghu Street Suzhou Industrial Park
Suzhou 215024
China
86 512 6285 0800
https://www.alphamabonc.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees366

Key Executives

NameTitlePayExercisedYear Born
Dr. Ting Xu Ph.D.Founder, Exec. Chairman & CEON/AN/A1973
Mr. Weihao XuChief Financial OfficerN/AN/A1983
Ms. Yang LiuVP of Corp. Operations & Exec. DirectorN/AN/A1972
Ms. Jin'nan WangDirector of Investor Relations & Joint Company Sec.N/AN/A1982
Mr. Yumin WanVP of Gov. Affairs & PRN/AN/A1972
Dr. Mike Liu M.B.A., Ph.D.Sr. VP of Bus. Devel.N/AN/A1966
Dr. Johannes NippgenChief Medical OfficerN/AN/A1968
Mr. Jing HanChief Commercial OfficerN/AN/AN/A
Ms. Lok Yee Chan A.C.I.S., A.C.S.Joint Company Sec.N/AN/A1991
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Alphamab Oncology, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.

Corporate Governance

Alphamab Oncology’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement